{"filing":{"accession_number":"0000896264-26-000050","cik":"0000896264","ticker":"USNA","company_name":"USANA HEALTH SCIENCES INC","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"usna-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/896264/000089626426000050/usna-20260804.htm"},"events":[{"id":23631,"run_id":21371,"accession_number":"0000896264-26-000050","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"USANA issued a press release on August 4, 2026 announcing Q2 2026 financial results (ended July 4, 2026) with net sales of $223 million, a net loss of $(21.4) million (including a $29.1 million goodwill impairment charge), and diluted EPS of $(1.16), along with downward-revised full-year 2026 guidance.","company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":23924,"accession_number":"0000896264-26-000050","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"USANA issued a press release on August 4, 2026 announcing financial results for Q2 2026 ended July 4, 2026, disclosing net sales of $223 million, a net loss of $(21.4) million (including a $29.1 million goodwill impairment charge), and diluted EPS of $(1.16). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes key metrics, segment performance, balance sheet data, and updated fiscal 2026 guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T00:15:18.356088+00:00","company_name":"","ticker":null,"filing_date":""},{"id":23925,"accession_number":"0000896264-26-000050","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 (ended July 4, 2026) disclosing net sales of $223 million, a net loss of $(21.4) million (including a $29.1 million goodwill impairment charge), and diluted EPS of $(1.16). The filing incorporates the earnings release by reference under Item 7.01 (Regulation FD Disclosure), with the full press release attached as EX-99.1. The company also updated its full-year 2026 guidance downward, reflecting lower-than-expected performance from Hiya and Rise Wellness segments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T00:15:18.356088+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23924,"accession_number":"0000896264-26-000050","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"USANA issued a press release on August 4, 2026 announcing financial results for Q2 2026 ended July 4, 2026, disclosing net sales of $223 million, a net loss of $(21.4) million (including a $29.1 million goodwill impairment charge), and diluted EPS of $(1.16). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes key metrics, segment performance, balance sheet data, and updated fiscal 2026 guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T00:15:18.356088+00:00","company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","filing_date":"2026-08-04"},{"id":23925,"accession_number":"0000896264-26-000050","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 (ended July 4, 2026) disclosing net sales of $223 million, a net loss of $(21.4) million (including a $29.1 million goodwill impairment charge), and diluted EPS of $(1.16). The filing incorporates the earnings release by reference under Item 7.01 (Regulation FD Disclosure), with the full press release attached as EX-99.1. The company also updated its full-year 2026 guidance downward, reflecting lower-than-expected performance from Hiya and Rise Wellness segments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T00:15:18.356088+00:00","company_name":"USANA HEALTH SCIENCES INC","ticker":"USNA","filing_date":"2026-08-04"}]}